title: Ergocalciferol versus calcitriol for controlling chronic kidney disease mineral bone disorder in stage 3 to 5 CKD: A randomized controlled trial.
abstract: To compare the efficacy and safety of ergocalciferol and calcitriol in stage 3 to 5 chronic kidney disease (CKD) patients, a randomized, prospective, controlled, open-labeled study was designed. 204 patients were enrolled into the present study with following-up duration of 33.2±3.8 months. Patients in Group VitD2 (n=104) and Group aVitD3 (n=100) were treated by ergocalciferol and calcitriol, respectively. The 25-hydroxyvitamin D levels of group VitD2 increased significantly from 15.14±7.46 to 37.32±10.49ng/ml (P<0.001, t=-19.692) and increased more (P<0.001, t=-14.982) than those of group aVitD3, which increased from 14.90±6.15 to 18.08±7.55ng/ml. Maintenance target levels of serum calcium, phosphorus, and intact parathyroid hormone as the primary outcome measure did not show significant difference in frequencies between two groups. In summary, treatment of CKD-mineral and bone disorders in CKD patients at stages 3 to 5 using ergocalciferol has a similar long-term efficacy and safety profile as calcitriol.
authors.affiliation: Department of Nephrology, Peking University International Hospital, No.1 Life Park Road, Zhongguancun Life Park, Changping District, Beijing, PR China. Electronic address: zhangdongliang@pkuih.edu.cn.
authors.forename: Dongliang
authors.initials: D
authors.lastname: Zhang
authors.affiliation: Faculty of Nephrology, Capital Medical University, PR China; Department of Nephrology, Beijing Friendship Hospital of Capital Medical University, PR China.
authors.forename: He
authors.initials: H
authors.lastname: Li
authors.affiliation: George Warren Brown School, Washington University, USA.
authors.forename: Daoxin
authors.initials: D
authors.lastname: Yin
authors.affiliation: Department of Nephrology, Beijing Friendship Hospital of Capital Medical University, PR China.
authors.forename: LiYan
authors.initials: L
authors.lastname: Wang
authors.affiliation: Department of Nephrology, Beijing Rehabilitation Hospital of Capital Medical University, PR China.
authors.forename: Yao
authors.initials: Y
authors.lastname: Ma
mesh_terms: D015415:Biomarkers / Q000378:metabolism; D002117:Calcitriol / Q000009:adverse effects / Q000627:therapeutic use*; D012080:Chronic Kidney Disease-Mineral and Bone Disorder / Q000188:drug therapy* / Q000378:metabolism; D004872:Ergocalciferols / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012449:Safety; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D004872:Ergocalciferols; D002117:Calcitriol
keywords: 25-Hydroxyvitamin D; Calcifediol, 25 hydroxyvitamin D3 (PubChem CID: 5283731); Calcitriol; Calcitriol (PubChem CID: 5280453); Chronic kidney disease mineral bone disorder; Ercalcidiol, 25 hydroxyvitamin D2 (PubChem CID: 9547260); Ergocalciferol; Ergocalciferol (PubChem CID: 5280793); Parathyroid hormone; Parathyroid hormone (1–34)(human) (PubChem CID: 16133850)